Glucose 6 Phosphatase Dehydrogenase (G6PD) and Neurodegenerative Disorders: Mapping Diagnostic and Therapeutic Opportunities

Overview

Journal Genes Dis

Date 2018 Sep 28

PMID 30258923

Citations 22

Authors

Manju Tiwari

Affiliations

Soon will be listed here.

Abstract

Glucose 6 phosphate dehydrogenase (G6PD) is a key and rate limiting enzyme in the pentose phosphate pathway (PPP). The physiological significance of enzyme is providing reduced energy to specific cells like erythrocyte by maintaining co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH). There are preponderance research findings that demonstrate the enzyme (G6PD) role in the energy balance, and it is associated with blood-related diseases and disorders, primarily the anemia resulted from G6PD deficiency. The X-linked genetic deficiency of G6PD and associated non-immune hemolytic anemia have been studied widely across the globe. Recent advancement in biology, more precisely neuroscience has revealed that G6PD is centrally involved in many neurological and neurodegenerative disorders. The neuroprotective role of the enzyme (G6PD) has also been established, as well as the potential of G6PD in oxidative damage and the Reactive Oxygen Species (ROS) produced in cerebral ischemia. Though G6PD deficiency remains a global health issue, however, a paradigm shift in research focusing the potential of the enzyme in neurological and neurodegenerative disorders will surely open a new avenue in diagnostics and enzyme therapeutics. Here, in this study, more emphasis was made on exploring the role of G6PD in neurological and inflammatory disorders as well as non-immune hemolytic anemia, thus providing diagnostic and therapeutic opportunities.

Citing Articles

Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative Diseases and Targeted Therapy.

Fang M, Zhou Y, He K, Lu Y, Tao F, Huang H Mol Neurobiol. 2025; .

PMID: 39987285 DOI: 10.1007/s12035-025-04775-y.

Revealing the secrets of Blue Zones.

Ulusu N Front Pharmacol. 2024; 15:1428111.

PMID: 39726786 PMC: 11669513. DOI: 10.3389/fphar.2024.1428111.

Mapping of the Glucose Metabolism Heterogeneity in Atherosclerosis: Correlation With 2-Deoxyglucose Uptake.

Haddad J, Demirdelen S, Barnes C, Leers S, Tavakoli S Mol Imaging. 2024; 23:15353508241280573.

PMID: 39568960 PMC: 11577107. DOI: 10.1177/15353508241280573.

Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction.

Prasad S, Acharjee A, Singh V, Trigun S, Acharjee P Metab Brain Dis. 2024; 39(8):1649-1665.

PMID: 39120853 DOI: 10.1007/s11011-024-01407-7.

The Effect of Neuronal CoQ Deficiency and Mitochondrial Dysfunction on a Rotenone-Induced Neuronal Cell Model of Parkinson's Disease.

Millichap L, Turton N, Damiani E, Marcheggiani F, Orlando P, Silvestri S Int J Mol Sci. 2024; 25(12).

PMID: 38928331 PMC: 11204355. DOI: 10.3390/ijms25126622.

References

Burton C, Kaczmarski R . Oxidative haemolysis secondary to high-dose vitamins in a woman with glucose-6-phosphate dehydrogenase deficiency. Br J Haematol. 2003; 121(2):201. DOI: 10.1046/j.1365-2141.2003.04205.x. View

Diaz-Flores M, Ibanez-Hernandez M, Galvan R, Gutierrez M, Duran-Reyes G, Medina-Navarro R . Glucose-6-phosphate dehydrogenase activity and NADPH/NADP+ ratio in liver and pancreas are dependent on the severity of hyperglycemia in rat. Life Sci. 2005; 78(22):2601-7. DOI: 10.1016/j.lfs.2005.10.022. View

Ho H, Cheng M, Chiu D . Glucose-6-phosphate dehydrogenase--beyond the realm of red cell biology. Free Radic Res. 2014; 48(9):1028-48. DOI: 10.3109/10715762.2014.913788. View

Huang Q, Aluise C, Joshi G, Sultana R, St Clair D, Markesbery W . Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. J Neurosci Res. 2010; 88(12):2618-29. DOI: 10.1002/jnr.22422. View

Palmer A . The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J Neural Transm (Vienna). 1999; 106(3-4):317-28. DOI: 10.1007/s007020050161. View

Wolk A, Larsson S, Johansson J, Ekman P . Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA. 2006; 296(11):1371-6. DOI: 10.1001/jama.296.11.1371. View

Besson M, Alegria K, Garrido-Gerter P, Barros L, Lievens J . Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model. PLoS One. 2015; 10(3):e0118765. PMC: 4356621. DOI: 10.1371/journal.pone.0118765. View

Verma M, Sobha K . Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects. Inflamm Res. 2015; 64(9):647-59. DOI: 10.1007/s00011-015-0843-8. View

Mesner O, Hammerman C, Goldschmidt D, Rudensky B, Bader D, Kaplan M . Glucose-6-phosphate dehydrogenase activity in male premature and term neonates. Arch Dis Child Fetal Neonatal Ed. 2004; 89(6):F555-7. PMC: 1721798. DOI: 10.1136/adc.2004.049148. View

10.

Beutler E, Vulliamy T . Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis. 2002; 28(2):93-103. DOI: 10.1006/bcmd.2002.0490. View

11.

Jinnah H, Sabina R, Van Den Berghe G . Metabolic disorders of purine metabolism affecting the nervous system. Handb Clin Neurol. 2013; 113:1827-36. PMC: 4215161. DOI: 10.1016/B978-0-444-59565-2.00052-6. View

12.

Babu G, Kumar A, Chandra R, Puri S, Singh R, Kalita J . Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem Int. 2008; 52(6):1284-9. DOI: 10.1016/j.neuint.2008.01.009. View

13.

Russell R, Siedlak S, Raina A, Bautista J, Smith M, Perry G . Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys. 1999; 370(2):236-9. DOI: 10.1006/abbi.1999.1404. View

14.

Takizawa T, Huang I, Ikuta T, Yoshida A . Human glucose-6-phosphate dehydrogenase: primary structure and cDNA cloning. Proc Natl Acad Sci U S A. 1986; 83(12):4157-61. PMC: 323690. DOI: 10.1073/pnas.83.12.4157. View

15.

Ferreira I, Cunha-Oliveira T, Nascimento M, Ribeiro M, Proenca M, Januario C . Bioenergetic dysfunction in Huntington's disease human cybrids. Exp Neurol. 2011; 231(1):127-34. DOI: 10.1016/j.expneurol.2011.05.024. View

16.

Lee J, Choi A, Ham M, Kim J, Choe S, Park J . G6PD up-regulation promotes pancreatic beta-cell dysfunction. Endocrinology. 2011; 152(3):793-803. DOI: 10.1210/en.2010-0606. View

17.

Maronpot R . Erythrocyte glucose-6-phosphate dehydrogenase and glutathione deficiency in sheep. Can J Comp Med. 1972; 36(1):55-60. PMC: 1319657. View

18.

Gray G, Stamatoyannopoulos G, Naiman S, KLIMAN M, Klebanoff S, Austin T . Neutrophil dysfunction, chronic granulomatous disease, and non-spherocytic haemolytic anaemia caused by complete deficiency of glucose-6-phosphate dehydrogenase. Lancet. 1973; 2(7828):530-4. DOI: 10.1016/s0140-6736(73)92350-7. View

19.

Yik J, Hu Z, Kumari R, Christiansen B, Haudenschild D . Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokines. Arthritis Rheumatol. 2014; 66(6):1537-46. PMC: 4127300. DOI: 10.1002/art.38378. View

20.

Verma M, Pulicherla K . Broad substrate affinity and catalytic diversity of fibrinolytic enzyme from Pheretima posthumous-Purification and molecular characterization study. Int J Biol Macromol. 2016; 95:1011-1021. DOI: 10.1016/j.ijbiomac.2016.10.090. View